@misc{10481/61996,
year = {2020},
month = {3},
url = {http://hdl.handle.net/10481/61996},
abstract = {The proposal of gene therapy to tackle cancer development has been instrumental for the
development of novel approaches and strategies to fight this disease, but the efficacy of the proposed
strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the
plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference,
gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and
tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome
this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular
focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for
cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical
development and their progress towards clinical applications.},
organization = {This work was supported by the Applied Molecular Biosciences Unit - UCIBIO which is financed by
national funds from FCT (UIDB/04378/2020), CRR (SFRH/BPD/124612/2016) and LRG (Inn-Indigo 00002/2015 RA
Detect).},
publisher = {MDPI},
keywords = {Gene therapy},
keywords = {Gene delivery},
keywords = {Tumor Microenvironment},
keywords = {Nanoparticles},
keywords = {Nanomedicine},
title = {Gene Therapy in Cancer Treatment: Why Go Nano?},
doi = {10.3390/pharmaceutics12030233},
author = {Roma Rodrigues, Catarina and Rivas-García, Lorenzo and Baptista, Pedro V. and Fernandes, Alexandra R.},
}